119 related articles for article (PubMed ID: 20636367)
21. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
22. EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls.
Mameli G; Cossu D; Cocco E; Masala S; Frau J; Marrosu MG; Sechi LA
J Neuroimmunol; 2013 Nov; 264(1-2):120-2. PubMed ID: 24099984
[TBL] [Abstract][Full Text] [Related]
23. A systematic study of Epstein-Barr virus serologic assays following acute infection.
Rea TD; Ashley RL; Russo JE; Buchwald DS
Am J Clin Pathol; 2002 Jan; 117(1):156-61. PubMed ID: 11789721
[TBL] [Abstract][Full Text] [Related]
24. Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.
Yamazaki M; Kitamura R; Kusano S; Eda H; Sato S; Okawa-Takatsuji M; Aotsuka S; Yanagi K
Clin Exp Immunol; 2005 Mar; 139(3):558-68. PubMed ID: 15730403
[TBL] [Abstract][Full Text] [Related]
25. Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Strautins K; Tschochner M; James I; Choo L; Dunn DS; Pedrini M; Kermode A; Carroll W; Nolan D
Mult Scler; 2014 Mar; 20(3):286-94. PubMed ID: 23886832
[TBL] [Abstract][Full Text] [Related]
26. An Epstein Barr virus-related cross reactive autoimmune response in multiple sclerosis in Norway.
Vaughan JH; Riise T; Rhodes GH; Nguyen MD; Barrett-Connor E; Nyland H
J Neuroimmunol; 1996 Sep; 69(1-2):95-102. PubMed ID: 8823380
[TBL] [Abstract][Full Text] [Related]
27. Epstein-barr virus and multiple sclerosis risk in the finnish maternity cohort.
Munger KL; Hongell K; Cortese M; Åivo J; Soilu-Hänninen M; Surcel HM; Ascherio A
Ann Neurol; 2019 Sep; 86(3):436-442. PubMed ID: 31226219
[TBL] [Abstract][Full Text] [Related]
28. The serological signs of the Epstein-Barr virus (EBV) activity in the elderly.
Ternák G; Szúcs G; Uj M
Acta Microbiol Immunol Hung; 1997; 44(2):133-40. PubMed ID: 9330661
[TBL] [Abstract][Full Text] [Related]
29. Immune responses to EBNA1: biomarkers in MS?
Lünemann JD; Ascherio A
Neurology; 2009 Jul; 73(1):13-4. PubMed ID: 19458320
[No Abstract] [Full Text] [Related]
30. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.
Bosseboeuf A; Feron D; Tallet A; Rossi C; Charlier C; Garderet L; Caillot D; Moreau P; Cardó-Vila M; Pasqualini R; Arap W; Nelson AD; Wilson BS; Perreault H; Piver E; Weigel P; Girodon F; Harb J; Bigot-Corbel E; Hermouet S
JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978808
[TBL] [Abstract][Full Text] [Related]
31. Smoking and Epstein-Barr virus infection in multiple sclerosis development.
Hedström AK; Huang J; Brenner N; Butt J; Hillert J; Waterboer T; Kockum I; Olsson T; Alfredsson L
Sci Rep; 2020 Jul; 10(1):10960. PubMed ID: 32620875
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of Epstein-Barr virus antibody in the chronic hemodialysed population in the south of the Reunion Island.
Guiserix J; Michault A; Ramdane M; Finielz P; Rajaonarivelo P
Nephron; 1996; 74(2):475. PubMed ID: 8893196
[No Abstract] [Full Text] [Related]
33. [Prevalence of anti-Epstein-Barr virus antibodies in children and adolescents with secondary immunodeficiency].
Bucková A
Epidemiol Mikrobiol Imunol; 2010 Aug; 59(3):133-7. PubMed ID: 20925250
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of IgG-IgM antibodies against the Epstein-Barr virus nuclear antigen (EBNA-1) using ELISA].
Martínez Zapico R; Sobejano L; Llamazares I; Ladrón de Guevara C
Enferm Infecc Microbiol Clin; 1992 May; 10(5):281-3. PubMed ID: 1327168
[TBL] [Abstract][Full Text] [Related]
35. Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern.
De Paschale M; Agrappi C; Manco MT; Mirri P; Viganò EF; Clerici P
J Med Virol; 2009 Feb; 81(2):325-31. PubMed ID: 19107979
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic evaluation of a new panel of assays for Epstein-Barr virus serology.
Radtke M; Gärtner B; Franke D
Clin Lab; 2007; 53(3-4):149-50. PubMed ID: 17447650
[No Abstract] [Full Text] [Related]
37. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up.
DeLorenze GN; Munger KL; Lennette ET; Orentreich N; Vogelman JH; Ascherio A
Arch Neurol; 2006 Jun; 63(6):839-44. PubMed ID: 16606758
[TBL] [Abstract][Full Text] [Related]
38. [Fluctuation in Epstein-Barr virus-related antibody titers by age: response differences between the IgG antibodies to VCA and anti-EBNA antibodies].
Kumagai E; Tanaka R; Kumagai T; Katsuki T; Sawada S
Rinsho Byori; 1984 Jun; 32(6):666-70. PubMed ID: 6092744
[No Abstract] [Full Text] [Related]
39. Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers.
Dobson R; Topping J; Giovannoni G
J Med Virol; 2013 Jan; 85(1):128-31. PubMed ID: 23154877
[TBL] [Abstract][Full Text] [Related]
40. The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
Dooley MM; de Gannes SL; Fu KA; Lindsey JW
J Neuroimmunol; 2016 Oct; 299():147-151. PubMed ID: 27725113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
